Eli Lilly and Company announced executive leadership changes and the creation of neuroscience and immunology business units. These changes will increase Lilly's focus on introducing breakthrough new medicines to millions of people with unmet needs.
Eli Lilly has received approval in Germany for Axiron (estosterone solution 2%) for testosterone replacement therapy for male Hypogonadism when...
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently...
Q3 financial statement from Eli Lilly: In October 2021, Eli Lilly and Pfizer discontinued the global clinical development program for tanezumab, an investigational nerve growth factor inhibitor.
Eli Lilly and Company and Incyte Corporation announced that Lilly has submitted a new drug application (NDA) to the FDA...
Eli Lilly and Company announced that the FDA has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of...
Eli Lilly has announced the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the...
To improve the understanding and advance the treatment of migraine, Eli Lilly and Company presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the American Headache Society (AHS) 2021 Virtual Annual Scientific Meeting, June 3-6 .
Boehringer Ingelheim and Eli Lilly and Company have announced top-line results for four completed Phase III clinical trials for empagliflozin,...
The FDA has approved various strengths of generic formulations of Eli Lilly's antidepressant Cymbalta (duloxetine), following the recent loss of...